Cushing’s syndrome: an update on current pharmacotherapy and future directions

Bibliography

• Lacroix A, Feelders R, Stratakis CA, Nieman L. Cushing’s syndrome. Lancet 2015. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Pereira AM, Tiemensma J, Romijn JA. Neuropsychiatric disorders in Cushing’s syndrome. Neuroendocrinology 2010;92:65-70
   PubMed Web of Science ®Google Scholar
• Stuijver DJ, van Zaane B, Feelders RA, et al. Incidence of venous thromboembolism in patients with Cushing’s syndrome: a multicenter cohort study. J Clin Endocrinol Metab 2011;96(11):3525-32
   PubMed Web of Science ®Google Scholar
• Dekkers OM, Horvath-Puho E, Jorgensen JO, et al. Multisystem morbidity and mortality in Cushing’s syndrome: a cohort study. J Clin Endocrinol Metab 2013;98(6):2277-84
   PubMed Web of Science ®Google Scholar
• Clayton RN, Raskauskiene D, Reulen RC, Jones PW. Mortality and Morbidity in Cushing’s Disease over 50 Years in Stoke-on-Trent, UK: Audit and Meta-Analysis of Literature. J Clin Endocr Metab 2011;96(3):632-42
   PubMed Web of Science ®Google Scholar
• Feelders RA, Pulgar SJ, Kempel A, Pereira AM. The burden of Cushing’s disease: clinical and health-related quality of life aspects. Eur J Endocrinol 2012;167(3):311-26
   PubMed Web of Science ®Google Scholar
• Hassan-Smith ZK, Sherlock M, Reulen RC, et al. Outcome of Cushing’s Disease following Transsphenoidal Surgery in a Single Center over 20 Years. J Clin Endocr Metab 2012;97(4):1194-201
   PubMed Web of Science ®Google Scholar
• Dekkers OM, Biermasz NR, Pereira AM, et al. Mortality in patients treated for Cushing’s disease is increased, compared with patients treated for nonfunctioning pituitary macroadenoma. J Clin Endocr Metab 2007;92(3):976-81
   PubMed Web of Science ®Google Scholar
• Lindsay JR, Nansel T, Baid S, et al. Long-term impaired quality of life in Cushing’s syndrome despite initial improvement after surgical remission. J Clin Endocr Metab 2006;91(2):447-53
   PubMed Web of Science ®Google Scholar
• Nieman LK, Biller BMK, Findling JW, et al. The diagnosis of Cushing’s syndrome: An endocrine society clinical practice guideline. J Clin Endocr Metab 2008;93(5):1526-40
   PubMed Web of Science ®Google Scholar
• De Leo M, Cozzolino A, Colao A, Pivonello R. Subclinical Cushing’s syndrome. Best Pract Res Clin Endocrinol Metab 2012;26(4):497-505
   PubMed Web of Science ®Google Scholar
• Biller BM, Grossman AB, Stewart PM, et al. Treatment of adrenocorticotropin-dependent Cushing’s syndrome: a consensus statement. J Clin Endocrinol Metab 2008;93(7):2454-62
   PubMed Web of Science ®Google Scholar
• Atkinson AB, Kennedy A, Wiggam MI, et al. Long-term remission rates after pituitary surgery for Cushing’s disease: the need for long-term surveillance. Clin Endocrinol (Oxf) 2005;63(5):549-59
   PubMed Web of Science ®Google Scholar
• Rees DA, Hanna FWF, Davies JS, et al. Long-term follow-up results of transsphenoidal surgery for Cushing’s disease in a single centre using strict criteria for remission. Clin Endocrinol 2002;56(4):541-51
   PubMed Web of Science ®Google Scholar
• Alexandraki KI, Kaltsas GA, Isidori AM, et al. Long-term remission and recurrence rates in Cushing’s disease: predictive factors in a single-centre study. Eur J Endocrinol 2013;168(4):639-48
   PubMed Web of Science ®Google Scholar
• Wagenmakers MAEM, Netea-Maier RT, van Lindert EJ, et al. Repeated transsphenoidal pituitary surgery (TS) via the endoscopic technique: a good therapeutic option for recurrent or persistent Cushing’s disease (CD). Clin Endocrinol 2009;70(2):274-80
   PubMed Web of Science ®Google Scholar
• Valderrabano P, Aller J, Garcia-Valdecasas L, et al. Results of repeated transsphenoidal surgery in Cushing’s disease. Long-term follow-up. Endocrinol Nutr 2014;61(4):176-83
   PubMedGoogle Scholar
• Benveniste RJ, King WA, Walsh J, et al. Repeated transsphenoidal surgery to treat recurrent or residual pituitary adenoma. J Neurosurg 2005;102(6):1004-12
   PubMed Web of Science ®Google Scholar
• Boscaro M, Barzon L, Fallo F, Sonino N. Cushing’s syndrome. Lancet 2001;357(9258):783-91
   PubMed Web of Science ®Google Scholar
• Petit JH, Biller BMK, Yock TI, et al. Proton stereotactic radiotherapy for persistent adrenocorticotropin-producing adenomas. J Clin Endocr Metab 2008;93(2):393-9
   PubMed Web of Science ®Google Scholar
• Starke RM, Williams BJ, Vance ML, Sheehan JP. Radiation therapy and stereotactic radiosurgery for the treatment of Cushing’s disease: an evidence-based review. Curr Opin Endocrinol Diabetes Obes 2010;17(4):356-64
   PubMed Web of Science ®Google Scholar
• Wattson DA, Tanguturi SK, Spiegel DY, et al. Outcomes of proton therapy for patients with functional pituitary adenomas. Int J Radiat Oncol Biol Phys 2014;90(3):532-9
   PubMed Web of Science ®Google Scholar
• Osswald A, Plomer E, Dimopoulou C, et al. Favorable long-term outcomes of bilateral adrenalectomy in Cushing’s disease. Eur J Endocrinol 2014;171(2):209-15
   PubMed Web of Science ®Google Scholar
• Patel J, Eloy JA, Liu JK. Nelson’s syndrome: a review of the clinical manifestations, pathophysiology, and treatment strategies. Neurosurg Focus 2015;38(2):E14
   PubMed Web of Science ®Google Scholar
• Smith PW, Turza KC, Carter CO, et al. Bilateral adrenalectomy for refractory Cushing disease: a safe and definitive therapy. J Am Coll Surg 2009;208(6):1059-64
   PubMed Web of Science ®Google Scholar
• Vella A, Thompson GB, Grant CS, et al. Laparoscopic adrenalectomy for adrenocorticotropin-dependent Cushing’s syndrome. J Clin Endocrinol Metab 2001;86(4):1596-9
   PubMed Web of Science ®Google Scholar
• Ilias I, Torpy DJ, Pacak K, et al. Cushing’s syndrome due to ectopic corticotropin secretion: twenty years’ experience at the National Institutes of Health. J Clin Endocrinol Metab 2005;90(8):4955-62
   PubMed Web of Science ®Google Scholar
• Isidori AM, Kaltsas GA, Pozza C, et al. The ectopic adrenocorticotropin syndrome: clinical features, diagnosis, management, and long-term follow-up. J Clin Endocrinol Metab 2006;91(2):371-7
   PubMed Web of Science ®Google Scholar
• Tritos NA, Biller BM, Swearingen B. Management of Cushing disease. Nat Rev Endocrinol 2011;7(5):279-89
   PubMed Web of Science ®Google Scholar
• Aniszewski JP, Young WFJr, Thompson GB, et al. Cushing syndrome due to ectopic adrenocorticotropic hormone secretion. World J Surg 2001;25(7):934-40
   PubMed Web of Science ®Google Scholar
• Yaneva M, Vandeva S, Zacharieva S, et al. Genetics of Cushing’s syndrome. Neuroendocrinology 2010;92(Suppl 1):6-10
   PubMed Web of Science ®Google Scholar
• Lacroix A. ACTH-independent macronodular adrenal hyperplasia. Best Pract Res Clin Endocrinol Metab 2009;23(2):245-59
   PubMed Web of Science ®Google Scholar
• Mauras N, Blizzard RM. The McCune-Albright syndrome. Acta Endocrinol Suppl (Copenh) 1986;279:207-17
   PubMedGoogle Scholar
• Assie G, Libe R, Espiard S, et al. ARMC5 mutations in macronodular adrenal hyperplasia with Cushing’s syndrome. N Engl J Med 2013;369(22):2105-14
   PubMed Web of Science ®Google Scholar
• Alencar GA, Lerario AM, Nishi MY, et al. ARMC5 mutations are a frequent cause of primary macronodular adrenal Hyperplasia. J Clin Endocrinol Metab 2014;99(8):E1501-9
   PubMed Web of Science ®Google Scholar
• Louiset E, Duparc C, Young J, et al. Intraadrenal corticotropin in bilateral macronodular adrenal hyperplasia. N Engl J Med 2013;369(22):2115-25
   PubMed Web of Science ®Google Scholar
• Stratakis CA. Cushing syndrome caused by adrenocortical tumors and hyperplasias (corticotropin- independent Cushing syndrome). Endocr Dev 2008;13:117-32
   PubMedGoogle Scholar
• Courcoutsakis N, Prassopoulos P, Stratakis CA. CT findings of primary pigmented nodular adrenocortical disease: rare cause of ACTH-independent Cushing syndrome. AJR Am J Roentgenol 2010;194(6):W541
   PubMed Web of Science ®Google Scholar
• Lacroix A, N’Diaye N, Tremblay J, Hamet P. Ectopic and abnormal hormone receptors in adrenal Cushing’s syndrome. Endocr Rev 2001;22(1):75-110
   PubMed Web of Science ®Google Scholar
• Cuesta MA, Bonjer HJ, van Mourik JC. Endoscopic adrenalectomy: the adrenals under the scope? Clin Endocrinol (Oxf) 1996;44(3):349-51
   PubMed Web of Science ®Google Scholar
• Lindsay JR, Nieman LK. Differential diagnosis and imaging in Cushing’s syndrome. Endocrin Metab Clin 2005;34(2):403
   Web of Science ®Google Scholar
• Lerario AM, Moraitis A, Hammer GD. Genetics and epigenetics of adrenocortical tumors. Mol Cell Endocrinol 2014;386(1-2):67-84
   PubMed Web of Science ®Google Scholar
• Luton JP, Cerdas S, Billaud L, et al. Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. N Engl J Med 1990;322(17):1195-201
   PubMed Web of Science ®Google Scholar
• Stojadinovic A, Ghossein RA, Hoos A, et al. Adrenocortical carcinoma: Clinical, morphologic, and molecular characterization. J Clin Oncol 2002;20(4):941-50
   PubMed Web of Science ®Google Scholar
• Fassnacht M, Johanssen S, Fenske W, et al. Improved survival in patients with stage II adrenocortical carcinoma followed up prospectively by specialized centers. J Clin Endocrinol Metab 2010;95(11):4925-32
   PubMed Web of Science ®Google Scholar
• Schulick RD, Brennan MF. Long-term survival after complete resection and repeat resection in patients with adrenocortical carcinoma. Ann Surg Oncol 1999;6(8):719-26
   PubMed Web of Science ®Google Scholar
• Terzolo M, Angeli A, Fassnacht M, et al. Adjuvant mitotane treatment for adrenocortical carcinoma. N Engl J Med 2007;356(23):2372-80
   PubMed Web of Science ®Google Scholar
• van der Pas R, de Herder WW, Hofland LJ, Feelders RA. New developments in the medical treatment of Cushing’s syndrome. Endocr Relat Cancer 2012;19(6):R205-23
   PubMed Web of Science ®Google Scholar
• de Bruin C, Pereira AM, Feelders RA, et al. Coexpression of dopamine and somatostatin receptor subtypes in corticotroph adenomas. J Clin Endocrinol Metab 2009;94(4):1118-24
   PubMed Web of Science ®Google Scholar
• Bruns C, Lewis I, Briner U, et al. SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol 2002;146(5):707-16
   PubMed Web of Science ®Google Scholar
• Hofland LJ, van der Hoek J, Feelders R, et al. The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5. Eur J Endocrinol 2005;152(4):645-54
   PubMed Web of Science ®Google Scholar
• Lamberts SWJ, Uitterlinden P, Klijn JMG. The Effect of the long-acting somatostatin analog sms-201-995 on acth-secretion in nelsons syndrome and cushings-disease. Acta Endocrinol-Cop 1989;120(6):760-6
   PubMedGoogle Scholar
• Stalla GK, Brockmeier SJ, Renner U, et al. Octreotide exerts different effects in vivo and in vitro in Cushing’s disease. Eur J Endocrinol 1994;130(2):125-31
   PubMed Web of Science ®Google Scholar
• Henry RR, Ciaraldi TP, Armstrong D, et al. Hyperglycemia associated with pasireotide: results from a mechanistic study in healthy volunteers. J Clin Endocrinol Metab 2013;98(8):3446-53
   PubMed Web of Science ®Google Scholar
• Boscaro M, Ludlam WH, Atkinson B, et al. Treatment of pituitary-dependent Cushing’s disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial. J Clin Endocrinol Metab 2009;94(1):115-22
   PubMed Web of Science ®Google Scholar
• Pivonello R, Ferone D, de Herder WW, et al. Dopamine receptor expression and function in corticotroph pituitary tumors. J Clin Endocrinol Metab 2004;89(5):2452-62
   PubMed Web of Science ®Google Scholar
• Pivonello R, De Martino MC, Cappabianca P, et al. The medical treatment of Cushing’s disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery. J Clin Endocrinol Metab 2009;94(1):223-30
   PubMed Web of Science ®Google Scholar
• Schade R, Andersohn F, Suissa S, et al. Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med 2007;356(1):29-38
   PubMed Web of Science ®Google Scholar
• Zanettini R, Antonini A, Gatto G, et al. Valvular heart disease and the use of dopamine agonists for Parkinson’s disease. N Engl J Med 2007;356(1):39-46
   PubMed Web of Science ®Google Scholar
• Delgado V, Biermasz NR, van Thiel SW, et al. Changes in heart valve structure and function in patients treated with dopamine agonists for prolactinomas, a 2-year follow-up study. Clin Endocrinol 2012;77(1):99-105
   PubMed Web of Science ®Google Scholar
• Raverot G, Sturm N, de Fraipont F, et al. Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience. J Clin Endocrinol Metab 2010;95(10):4592-9
   PubMed Web of Science ®Google Scholar
• Dillard TH, Gultekin SH, Delashaw JBJr, et al. Temozolomide for corticotroph pituitary adenomas refractory to standard therapy. Pituitary 2011;14(1):80-91
   PubMed Web of Science ®Google Scholar
• Curto L, Torre ML, Ferrau F, et al. Temozolomide-induced shrinkage of a pituitary carcinoma causing Cushing’s disease--report of a case and literature review. ScientificWorldJournal 2010;10:2132-8
   PubMed Web of Science ®Google Scholar
• Mohammed S, Kovacs K, Mason W, et al. Use of temozolomide in aggressive pituitary tumors: case report. Neurosurgery 2009;64(4):E773-4
   PubMed Web of Science ®Google Scholar
• McCormack AI, Wass JA, Grossman AB. Aggressive pituitary tumours: the role of temozolomide and the assessment of MGMT status. Eur J Clin Invest 2011;41(10):1133-48
   PubMed Web of Science ®Google Scholar
• Bode H, Seiz M, Lammert A, et al. SOM230 (pasireotide) and temozolomide achieve sustained control of tumour progression and ACTH secretion in pituitary carcinoma with widespread metastases. Exp Clin Endocrinol Dia 2010;118(10):760-3
   PubMed Web of Science ®Google Scholar
• Engelhardt D, Weber MM, Miksch T, et al. The influence of ketoconazole on human adrenal steroidogenesis: incubation studies with tissue slices. Clin Endocrinol (Oxf) 1991;35(2):163-8
   PubMed Web of Science ®Google Scholar
• Engelhardt D, Dorr G, Jaspers C, Knorr D. Ketoconazole Blocks Cortisol Secretion in Man by Inhibition of Adrenal 11-Beta-Hydroxylase. Klin Wochenschr 1985;63(13):607-12
   PubMedGoogle Scholar
• Lamberts SW, Bons EG, Bruining HA, de Jong FH. Differential effects of the imidazole derivatives etomidate, ketoconazole and miconazole and of metyrapone on the secretion of cortisol and its precursors by human adrenocortical cells. J Pharmacol Exp Ther 1987;240(1):259-64
   PubMed Web of Science ®Google Scholar
• Mccance DR, Hadden DR, Kennedy L, et al. Clinical-Experience with Ketoconazole as a Therapy for Patients with Cushings-Syndrome. Clin Endocrinol 1987;27(5):593-9
   PubMed Web of Science ®Google Scholar
• Sonino N, Boscaro M, Paoletta A, et al. Ketoconazole Treatment in Cushings-Syndrome - Experience in 34 Patients. Clin Endocrinol 1991;35(4):347-52
   PubMed Web of Science ®Google Scholar
• Castinetti F, Morange I, Jaquet P, et al. Ketoconazole revisited: a preoperative or postoperative treatment in Cushing’s disease. Eur J Endocrinol 2008;158(1):91-9
   PubMed Web of Science ®Google Scholar
• Feelders RA, Hofland LJ, de Herder WW. Medical treatment of Cushing’s syndrome: adrenal-blocking drugs and ketaconazole. Neuroendocrinology 2010;92(Suppl 1):111-15
   PubMed Web of Science ®Google Scholar
• Stalla GK, Stalla J, Huber M, et al. Ketoconazole inhibits corticotropic cell-function invitro. Endocrinology 1988;122(2):618-23
   PubMed Web of Science ®Google Scholar
• Loli P, Berselli ME, Tagliaferri M. Use of ketoconazole in the treatment of Cushings-syndrome. J Clin Endocr Metab 1986;63(6):1365-71
   PubMed Web of Science ®Google Scholar
• Terzolo M, Panarelli M, Piovesan A, et al. ketoconazole treatment in cushings-disease - effect on the circadian profile of plasma acth and cortisol. J Endocrinol Invest 1988;11(10):717-21
   PubMed Web of Science ®Google Scholar
• Verhelst JA, Trainer PJ, Howlett TA, et al. Short and long-term responses to metyrapone in the medical management of 91 patients with Cushing’s syndrome. Clin Endocrinol (Oxf) 1991;35(2):169-78
   PubMed Web of Science ®Google Scholar
• Nieman LK. Medical therapy of Cushing’s disease. Pituitary 2002;5(2):77-82
   PubMedGoogle Scholar
• Stewart PM, Petersenn S. Rationale for treatment and therapeutic options in Cushing’s disease. Best Pract Res Clin Endocrinol Metab 2009;23(Suppl 1):S15-22
   PubMed Web of Science ®Google Scholar
• Monaghan PJ, Owen LJ, Trainer PJ, et al. Comparison of serum cortisol measurement by immunoassay and liquid chromatography-tandem mass spectrometry in patients receiving the 11beta-hydroxylase inhibitor metyrapone. Ann Clin Biochem 2011;48(Pt 5):441-6
   PubMed Web of Science ®Google Scholar
• Veytsman I, Nieman L, Fojo T. Management of endocrine manifestations and the use of mitotane as a chemotherapeutic agent for adrenocortical carcinoma. J Clin Oncol 2009;27(27):4619-29
   PubMed Web of Science ®Google Scholar
• Fassnacht M, Libe R, Kroiss M, Allolio B. Adrenocortical carcinoma: a clinician’s update. Nat Rev Endocrinol 2011;7(6):323-35
   PubMed Web of Science ®Google Scholar
• Hescot S, Slama A, Lombes A, et al. Mitotane alters mitochondrial respiratory chain activity by inducing cytochrome c oxidase defect in human adrenocortical cells. Endocr Relat Cancer 2013;20(3):371-81
   PubMed Web of Science ®Google Scholar
• Schteingart DE. Drugs in the medical treatment of Cushing’s syndrome. Expert Opin Emerg Dr 2009;14(4):661-71
   PubMed Web of Science ®Google Scholar
• Kroiss M, Quinkler M, Lutz WK, et al. Drug interactions with mitotane by induction of CYP3A4 metabolism in the clinical management of adrenocortical carcinoma. Clin Endocrinol 2011;75(5):585-91
   PubMed Web of Science ®Google Scholar
• Touitou Y, Bogdan A, Luton JP. Changes in corticosteroid synthesis of the human adrenal cortex in vitro, induced by treatment with o,p’-DDD for Cushing’s syndrome: evidence for the sites of action of the drug. J Steroid Biochem 1978;9(12):1217-24
   PubMedGoogle Scholar
• Ghataore L, Chakraborti I, Aylwin SJ, et al. Effects of mitotane treatment on human steroid metabolism: implications for patient management. Endocr Connect 2012;1(1):37-47
   PubMedGoogle Scholar
• Nader N, Raverot G, Emptoz-Bonneton A, et al. Mitotane has an estrogenic effect on sex hormone-binding globulin and corticosteroid-binding globulin in humans. J Clin Endocr Metab 2006;91(6):2165-70
   PubMed Web of Science ®Google Scholar
• Fassnacht M, Allolio B. Clinical management of adrenocortical carcinoma. Best Pract Res Clin Endocrinol Metab 2009;23(2):273-89
   PubMed Web of Science ®Google Scholar
• Fellows IW, Bastow MD, Byrne AJ, Allison SP. Adrenocortical suppression in multiply injured patients: a complication of etomidate treatment. Br Med J (Clin Res Ed) 1983;287(6408):1835-7
   PubMed Web of Science ®Google Scholar
• Drake WM, Perry LA, Hinds CJ, et al. Emergency and prolonged use of intravenous etomidate to control hypercortisolemia in a patient with Cushing’s syndrome and peritonitis. J Clin Endocrinol Metab 1998;83(10):3542-4
   PubMed Web of Science ®Google Scholar
• Preda VA, Sen J, Karavitaki N, Grossman AB. Etomidate in the management of hypercortisolaemia in Cushing’s syndrome: a review. Eur J Endocrinol 2012;167(2):137-43
   PubMed Web of Science ®Google Scholar
• Fleseriu M, Biller BM, Findling JW, et al. Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing’s syndrome. J Clin Endocrinol Metab 2012;97(6):2039-49
   PubMed Web of Science ®Google Scholar
• Castinetti F, Fassnacht M, Johanssen S, et al. Merits and pitfalls of mifepristone in Cushing’s syndrome. Eur J Endocrinol 2009;160(6):1003-10
   PubMed Web of Science ®Google Scholar
• Fleseriu M, Findling JW, Koch CA, et al. Changes in plasma ACTH levels and corticotroph tumor size in patients with Cushing’s disease during long-term treatment with the glucocorticoid receptor antagonist mifepristone. J Clin Endocrinol Metab 2014;99(10):3718-27
   PubMed Web of Science ®Google Scholar
• Feelders RA, de Bruin C, Pereira AM, et al. Pasireotide alone or with cabergoline and ketoconazole in Cushing’s disease. N Engl J Med 2010;362(19):1846-8
   PubMed Web of Science ®Google Scholar
• Colao A, Petersenn S, Newell-Price J, et al. A 12-month phase 3 study of pasireotide in Cushing’s disease. N Engl J Med 2012;366(10):914-24
   PubMed Web of Science ®Google Scholar
• Katznelson L. Sustained improvements in plasma ACTH and clinical status in a patient with Nelson’s syndrome treated with pasireotide LAR, a multireceptor somatostatin analog. J Clin Endocrinol Metab 2013;98(5):1803-7
   PubMed Web of Science ®Google Scholar
• Pivonello R, Petersenn S, Newell-Price J, et al. Pasireotide treatment significantly improves clinical signs and symptoms in patients with Cushing’s disease: results from a Phase III study. Clin Endocrinol (Oxf) 2014;81(3):408-17
   PubMed Web of Science ®Google Scholar
• Schopohl J, Gu F, Rubens R, et al. Pasireotide can induce sustained decreases in urinary cortisol and provide clinical benefit in patients with Cushing’s disease: results from an open-ended, open-label extension trial. Pituitary 2014
   Web of Science ®Google Scholar
• Breitschaft A, Hu K, Hermosillo Resendiz K, et al. Management of hyperglycemia associated with pasireotide (SOM230): healthy volunteer study. Diabetes Res Clin Pract 2014;103(3):458-65
   PubMed Web of Science ®Google Scholar
• Schmid HA, Brueggen J. Effects of somatostatin analogs on glucose homeostasis in rats. J Endocrinol 2012;212(1):49-60
   PubMed Web of Science ®Google Scholar
• Godbout A, Manavela M, Danilowicz K, et al. Cabergoline monotherapy in the long-term treatment of Cushing’s disease. Eur J Endocrinol 2010;163(5):709-16
   PubMed Web of Science ®Google Scholar
• Vilar L, Naves LA, Azevedo MF, et al. Effectiveness of cabergoline in monotherapy and combined with ketoconazole in the management of Cushing’s disease. Pituitary 2010;13(2):123-9
   PubMed Web of Science ®Google Scholar
• Barbot M, Albiger N, Ceccato F, et al. Combination therapy for Cushing’s disease: effectiveness of two schedules of treatment: should we start with cabergoline or ketoconazole? Pituitary 2014;17(2):109-17
   PubMed Web of Science ®Google Scholar
• Woo I, Ehsanipoor RM. Cabergoline therapy for Cushing disease throughout pregnancy. Obstet Gynecol 2013;122(2 Pt 2):485-7
   PubMed Web of Science ®Google Scholar
• Valassi E, Crespo I, Gich I, et al. A reappraisal of the medical therapy with steroidogenesis inhibitors in Cushing’s syndrome. Clin Endocrinol (Oxf) 2012;77(5):735-42
   PubMed Web of Science ®Google Scholar
• Castinetti F, Guignat L, Giraud P, et al. Ketoconazole in Cushing’s disease: is it worth a try? J Clin Endocrinol Metab 2014;99(5):1623-30
   PubMed Web of Science ®Google Scholar
• Luton JP, Mahoudeau JA, Bouchard P, et al. Treatment of Cushing’s disease by O,p’DDD. Survey of 62 cases. N Engl J Med 1979;300(9):459-64
   PubMed Web of Science ®Google Scholar
• Baudry C, Coste J, Bou Khalil R, et al. Efficiency and tolerance of mitotane in Cushing’s disease in 76 patients from a single center. Eur J Endocrinol 2012;167(4):473-81
   PubMed Web of Science ®Google Scholar
• Zacharia BE, Gulati AP, Bruce JN, et al. High response rates and prolonged survival in patients with corticotroph pituitary tumors and refractory Cushing disease from capecitabine and temozolomide (CAPTEM): a case series. Neurosurgery 2014;74(4):E447-55
   PubMed Web of Science ®Google Scholar
• Castinetti F, Brue T, Conte-Devolx B. The use of the glucocorticoid receptor antagonist mifepristone in Cushing’s syndrome. Curr Opin Endocrinol Diabetes Obes 2012;19(4):295-9
   PubMed Web of Science ®Google Scholar
• Kamenicky P, Droumaguet C, Salenave S, et al. Mitotane, metyrapone, and ketoconazole combination therapy as an alternative to rescue adrenalectomy for severe ACTH-dependent Cushing’s syndrome. J Clin Endocrinol Metab 2011;96(9):2796-804
   PubMed Web of Science ®Google Scholar
• Bertagna X, Pivonello R, Fleseriu M, et al. LCI699, a potent 11beta-hydroxylase inhibitor, normalizes urinary cortisol in patients with Cushing’s disease: results from a multicenter, proof-of-concept study. J Clin Endocrinol Metab 2014;99(4):1375-83
   PubMed Web of Science ®Google Scholar
• Paez-Pereda M, Kovalovsky D, Hopfner U, et al. Retinoic acid prevents experimental Cushing syndrome. J Clin Invest 2001;108(8):1123-31
   PubMed Web of Science ®Google Scholar
• Pecori Giraldi F, Ambrogio AG, Andrioli M, et al. Potential role for retinoic acid in patients with Cushing’s disease. J Clin Endocrinol Metab 2012;97(10):3577-83
   PubMed Web of Science ®Google Scholar
• Fukuoka H, Cooper O, Ben-Shlomo A, et al. EGFR as a therapeutic target for human, canine, and mouse ACTH-secreting pituitary adenomas. J Clin Invest 2011;121(12):4712-21
   PubMed Web of Science ®Google Scholar
• van der Pas R, Hofland LJ, Hofland J, et al. Fluconazole inhibits human adrenocortical steroidogenesis in vitro. J Endocrinol 2012;215(3):403-12
   PubMed Web of Science ®Google Scholar
• Riedl M, Maier C, Zettinig G, et al. Long term control of hypercortisolism with fluconazole: case report and in vitro studies. Eur J Endocrinol 2006;154(4):519-24
   PubMed Web of Science ®Google Scholar
• Rotstein DM, Kertesz DJ, Walker KA, Swinney DC. Stereoisomers of ketoconazole: preparation and biological activity. J Med Chem 1992;35(15):2818-25
   PubMed Web of Science ®Google Scholar
• van der Pas R, Feelders RA, Gatto F, et al. Preoperative normalization of cortisol levels in Cushing’s disease after medical treatment: consequences for somatostatin and dopamine receptor subtype expression and in vitro response to somatostatin analogs and dopamine agonists. J Clin Endocrinol Metab 2013;98(12):E1880-90
   PubMed Web of Science ®Google Scholar
• Sharma ST, Nieman LK. Prolonged remission after long-term treatment with steroidogenesis inhibitors in Cushing’s syndrome caused by ectopic ACTH secretion. Eur J Endocrinol 2012;166(3):531-6
   PubMed Web of Science ®Google Scholar
• Schulte HM, Benker G, Reinwein D, et al. Infusion of low dose etomidate: correction of hypercortisolemia in patients with Cushing’s syndrome and dose-response relationship in normal subjects. J Clin Endocrinol Metab 1990;70(5):1426-30
   PubMed Web of Science ®Google Scholar
• de Bruin C, Hofland LJ, Nieman LK, et al. Mifepristone effects on tumor somatostatin receptor expression in two patients with Cushing’s syndrome due to ectopic adrenocorticotropin secretion. J Clin Endocrinol Metab 2012;97(2):455-62
   PubMed Web of Science ®Google Scholar
• Pivonello R, Ferone D, de Herder WW, et al. Dopamine receptor expression and function in corticotroph ectopic tumors. J Clin Endocrinol Metab 2007;92(1):65-9
   PubMed Web of Science ®Google Scholar
• Sakihara S, Kageyama K, Yamagata S, et al. A case of ectopic ACTH syndrome treated with intermittent administration of dopamine agonists. Endocrinol Diab Metabol Case Rep 2014;2014:140001
   Google Scholar
• Pivonello R, Ferone D, Lamberts SW, Colao A. Cabergoline plus lanreotide for ectopic Cushing’s syndrome. N Engl J Med 2005;352(23):2457-8
   PubMed Web of Science ®Google Scholar
• Lacroix A, Tremblay J, Rousseau G, et al. Propranolol therapy for ectopic beta-adrenergic receptors adrenal Cushing’s syndrome. New Engl J Med 1997;337(20):1429-34
   PubMed Web of Science ®Google Scholar
• Reznik Y, Allali-Zerah V, Chayvialle JA, et al. Food-dependent Cushing’s syndrome mediated by aberrant adrenal sensitivity to gastric inhibitory polypeptide. N Engl J Med 1992;327(14):981-6
   PubMed Web of Science ®Google Scholar
• de Herder WW, Hofland LJ, Usdin TB, et al. Food-dependent Cushing’s syndrome resulting from abundant expression of gastric inhibitory polypeptide receptors in adrenal adenoma cells. J Clin Endocrinol Metab 1996;81(9):3168-72
   PubMed Web of Science ®Google Scholar
• Phan AT. Adrenal cortical carcinoma--review of current knowledge and treatment practices. Hematol Oncol Clin North Am 2007;21(3):489-507
   PubMed Web of Science ®Google Scholar
• Fassnacht M, Terzolo M, Allolio B, et al. Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med 2012;366(23):2189-97
   PubMed Web of Science ®Google Scholar
• O’Sullivan C, Edgerly M, Velarde M, et al. The VEGF Inhibitor Axitinib Has Limited Effectiveness as a Therapy for Adrenocortical Cancer. J Clin Endocr Metab 2014;99(4):1291-7
   PubMed Web of Science ®Google Scholar
• Lerario AM, Worden FP, Ramm CA, et al. The Combination of Insulin-Like Growth Factor Receptor 1 (IGF1R) Antibody Cixutumumab and Mitotane as a First-Line Therapy for Patients with Recurrent/Metastatic Adrenocortical Carcinoma: a Multi-institutional NCI-Sponsored Trial (vol 5, pg 232, 2014). Horm Cancer-Us 2014;8(6):424-4
   Web of Science ®Google Scholar
• Hofland J, Hofland LJ, van Koetsveld PM, et al. ACTH-independent macronodular adrenocortical hyperplasia reveals prevalent aberrant in vivo and in vitro responses to hormonal stimuli and coupling of arginine-vasopressin type 1a receptor to 11beta-hydroxylase. Orphanet J Rare Dis 2013;8:142
   PubMed Web of Science ®Google Scholar
• Volante M, Terzolo M, Fassnacht M, et al. Ribonucleotide Reductase Large Subunit (RRM1) Gene Expression May Predict Efficacy of Adjuvant Mitotane in Adrenocortical Cancer. Clin Cancer Res 2012;18(12):3452-61
   PubMed Web of Science ®Google Scholar
• Germano A, Rapa I, Volante M, et al. RRM1 modulates mitotane activity in adrenal cancer cells interfering with its metabolization. Mol Cell Endocrinol 2014;401C:105-10
   Google Scholar
• Germano A, Rapa I, Volante M, et al. Cytotoxic activity of gemcitabine, alone or in combination with mitotane, in adrenocortical carcinoma cell lines. Mol Cell Endocrinol 2014;382(1):1-7
   PubMed Web of Science ®Google Scholar
• van Koetsveld PM, Vitale G, Feelders RA, et al. Interferon-beta is a potent inhibitor of cell growth and cortisol production in vitro and sensitizes human adrenocortical carcinoma cells to mitotane. Endocr Relat Cancer 2013;20(3):443-54
   PubMed Web of Science ®Google Scholar